PRIME-HCC Trial: Neoadjuvant Nivolumab Plus Ipilimumab in Resectable Hepatocellular Carcinoma

PRIME-HCC Trial: Neoadjuvant Nivolumab Plus Ipilimumab in Resectable Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) remains associated with a substantial risk of recurrence after curative-intent liver resection. Although immune checkpoint inhibitors have changed the treatment landscape for advanced HCC, their role in patients with resectable disease is still being investigated.

Neoadjuvant immunotherapy has emerged as a potential strategy to improve outcomes in this setting. However, questions remain about its safety before liver surgery, its antitumor activity, and the biological factors associated with treatment response.

The PRIME-HCC trial investigated the feasibility and safety of neoadjuvant nivolumab plus ipilimumab in patients with resectable HCC, alongside translational analyses exploring immune responses and circulating tumor DNA (ctDNA) as potential biomarkers.

The study was published online in The Lancet Oncology on November 17, 2026, under the original title, “Neoadjuvant nivolumab plus ipilimumab in surgically resectable hepatocellular carcinoma (PRIME-HCC): a prospective, phase 1b, single-arm trial and translational analyses.”

The study was conducted by Antonio D’Alessio, Claudia Angela Maria Fulgenzi, Madhava Pai, Alexandra Emilia Schlaak, Duncan Spalding, Ira Godbole, Robert D Goldin, Nicole Acuti, Caroline Ward, Georgios Nteliopoulos, Vincent Yip, Sarah Slater, Poyyamozhi Rajagopal, Mikael Sodergren, Paul Tait, Nagy Habib, Robert Thomas, Eslam Maher, Francesco A Mauri, Alessio Cortellini, Julian R Marchesi, Bertram Bengsch, Rohini Sharma, and David James Pinato.

Study Design and Patient Population

PRIME-HCC (NCT03682276) was a prospective, open-label, single-arm phase Ib trial conducted in the United Kingdom. The study enrolled adults with resectable HCC, Child–Pugh A liver function, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1. Patients were considered suitable for liver resection but not for transplantation following multidisciplinary assessment. Previous systemic therapy was not permitted.

Participants received a short course of neoadjuvant immunotherapy consisting of nivolumab 3 mg/kg intravenously on days 1 and 22, together with a single dose of ipilimumab 1 mg/kg on day 1. Liver resection was subsequently planned, with no postoperative adjuvant therapy permitted by the protocol.

The primary endpoint was safety and tolerability, including treatment-related adverse events and unplanned delays to surgery. Secondary endpoints included radiological and pathological responses, while survival outcomes and biomarker analyses were exploratory.

The translational component incorporated peripheral immune profiling, imaging mass cytometry, spatial transcriptomics, T-cell receptor sequencing, and longitudinal ctDNA analysis.

Between September 2019 and September 2023, 43 patients were screened and 33 were enrolled. The median age was 68 years, 76% were male, and 52% had cirrhosis. Most patients had Barcelona Clinic Liver Cancer (BCLC) stage A disease (70%), while 30% had BCLC stage B disease.

ctDNA

Safety and Surgical Feasibility

At a median follow-up of 25.7 months (95% CI, 21.2–30.1), the primary safety analysis included all 33 patients who received at least one dose of immunotherapy. Any-grade adverse events occurred in 31 patients (94%), while treatment-related adverse events were reported in 25 patients (76%).

Grade 3 treatment-related adverse events occurred in three patients (9%), including two cases of immune-related hepatotoxicity and one episode of dyspnea and anemia associated with immune-related myocarditis. Serious adverse events were recorded in three patients (9%). No grade 4–5 adverse events or treatment-related deaths were reported.

Overall, 30 of 33 patients (91%) underwent surgery. Two patients (6%) experienced treatment-related surgical delays due to hypothyroidism and myocarditis, respectively, but both subsequently underwent liver resection.

Three patients did not proceed to surgery for reasons considered unrelated to immunotherapy. No patient was withdrawn from surgical plans because of treatment-related toxicity, and no immune-related adverse event was associated with perioperative morbidity or mortality. These findings supported the feasibility of administering a short course of nivolumab plus ipilimumab before planned liver surgery in this selected population.

Antitumor Activity and Survival Outcomes

The efficacy analysis included 32 patients after one participant was excluded following a diagnosis of cholangiocarcinoma on surgical pathology. According to RECIST version 1.1, the objective response rate (ORR) was 25% (8/32; 95% CI, 13–42), including one complete response and seven partial responses. The disease control rate was 97% (31/32; 95% CI, 84–100).

Using modified RECIST criteria, the ORR was 41% (13/32; 95% CI, 26–58), including two complete responses. Pathological response could be evaluated in 27 patients. A major pathological response, defined as at least 70% tumor regression, was observed in nine patients (33%; 95% CI, 19–52), while six patients (22%; 95% CI, 11–41) achieved a pathological complete response.

In a post-hoc analysis using a threshold of at least 90% tumor regression, the major pathological response rate was 30% (8/27). At the data cutoff, median overall survival (OS), event-free survival (EFS), and recurrence-free survival (RFS) had not been reached.

The estimated 2-year outcomes were:

  • EFS: 71% (95% CI, 55–92).
  • RFS: 69% (95% CI, 59–94).
  • OS: 90% (95% CI, 78–100).

These survival findings were descriptive, as the study was not designed to determine whether neoadjuvant immunotherapy improves survival compared with surgery alone.

PRIME-HCC Trial: Neoadjuvant Nivolumab Plus Ipilimumab in Resectable Hepatocellular Carcinoma

Translational Analyses: Immune Features Associated With Response

Beyond clinical outcomes, PRIME-HCC investigated immune changes associated with response or resistance to neoadjuvant nivolumab plus ipilimumab. Peripheral immune profiling showed that patients achieving objective responses had greater expansion of proliferating PD-1-positive, Ki-67-positive CD8-positive T cells, described as responding exhausted T cells (Tresp), following immunotherapy.

Analyses of paired tumor samples revealed that patients with objective responses had higher baseline levels of progenitor-exhausted CD8-positive T cells (Tpex), characterized by PD-1 and TCF1 expression. These patients also demonstrated greater infiltration of Tresp cells after treatment.

In contrast, patients without objective responses had higher baseline levels of terminally exhausted CD8-positive T cells (Tex-term) and regulatory T cells, together with increased expression of genes associated with T-cell exhaustion following treatment. Spatial transcriptomic analyses supported these findings, identifying distinct immune characteristics in the tumor microenvironment before and after treatment.

T-cell receptor sequencing also demonstrated greater peripheral clonal expansion in patients with objective responses. In the paired blood–tumor analysis involving nine patients, the proportion of T-cell clones that expanded in blood and were also detected in tumor tissue after treatment was higher among responders than nonresponders (57% vs 32%; p<0.0001).

Together, these exploratory findings suggested that differences in baseline T-cell populations and treatment-induced immune changes may contribute to the variable responses observed with dual checkpoint inhibition.

ctDNA Dynamics and Postoperative Outcomes

The study also explored whether longitudinal ctDNA monitoring could provide information about treatment response and postoperative recurrence risk. At baseline, ctDNA was detectable in 13 of 27 patients (48%). Among 18 patients with available postoperative samples, 11 (61%) had no detectable ctDNA after liver resection.

Postoperative ctDNA status was associated with subsequent outcomes. At 2 years, 9 of 11 patients (82%) without detectable postoperative ctDNA were relapse-free, compared with 2 of 7 (29%) patients with detectable postoperative ctDNA (p=0.049). Patients without detectable ctDNA after surgery also had longer median EFS, which was not reached compared with 16.8 months in patients with detectable postoperative ctDNA (HR 0.22; 95% CI, 0.05–0.98; p=0.031).

Among patients with detectable ctDNA, a reduction of at least 50% from baseline was associated with longer median EFS compared with patients without such a reduction (not reached vs 20.9 months; HR 0.14; 95% CI, 0.02–0.91; p=0.039).

All five available plasma samples collected at disease relapse had detectable ctDNA. However, baseline ctDNA detection was not significantly associated with radiological or major pathological response or with subsequent relapse outcomes.

Although these findings suggest that postoperative ctDNA dynamics may have prognostic value, the analyses involved small patient subgroups and relatively few events. The reported associations therefore require confirmation in larger prospective studies before ctDNA can be used to guide clinical decisions in this setting.

ESMO GI

What Do These Findings Mean for Clinical Practice?

The PRIME-HCC trial provides prospective evidence that a short course of neoadjuvant nivolumab plus ipilimumab is feasible in selected patients with resectable HCC, with most participants proceeding to surgery and relatively few treatment-related surgical delays.

The observed radiological and pathological responses also demonstrate antitumor activity, while the translational analyses offer additional insight into the immune characteristics associated with response and resistance.

An important aspect of the study is the integration of tissue-based immune profiling with longitudinal ctDNA monitoring. The associations between Tpex populations, treatment-induced T-cell expansion, postoperative ctDNA status, and clinical outcomes provide a basis for further biomarker research.

However, PRIME-HCC was a small, single-arm phase Ib trial primarily designed to assess safety, rather than establish an improvement in recurrence or survival. Its exploratory biomarker findings, particularly those involving ctDNA, should also be interpreted cautiously given the limited sample sizes.

The results support further investigation of neoadjuvant PD-1 and CTLA-4 blockade in resectable HCC, with randomized trials needed to establish its clinical benefit and prospective validation required to determine whether immune profiling and ctDNA monitoring can inform treatment decisions.

The full article is available in The Lancet Oncology.

Susanna Mikayelyan
Fact checked by Susanna Mikayelyan MD, Scientific Content Writer
Amalya Sargsyan
Medically reviewed by Amalya Sargsyan MD, Medical Oncologist